Histone deacetylase-based dual inhibitors: research progress focusing on non-small cell lung cancer therapy

Area of Science:

• Oncology
• Epigenetics
• Molecular Biology

Background:

• Epigenetic dysregulation, particularly involving histone deacetylases (HDACs), is crucial in non-small cell lung cancer (NSCLC) development, progression, and drug resistance.
• While HDAC inhibitors are effective in hematological cancers, their use in solid tumors like NSCLC is limited.
• HDACs are implicated in NSCLC malignancy and represent promising therapeutic targets.

Purpose of the Study:

• To review the current landscape of histone deacetylase (HDAC) dual-target inhibitors for non-small cell lung cancer (NSCLC).
• To highlight the advantages of dual-target inhibitors, including synergistic effects and improved resistance profiles.
• To identify challenges and provide insights for developing novel, effective, and less toxic NSCLC therapeutics.

Main Methods:

• Literature review of current research on HDAC inhibitors and dual-target strategies in NSCLC.
• Analysis of the mechanisms underlying HDAC aberrant activation in NSCLC.
• Evaluation of the efficacy and limitations of existing HDAC inhibitors in solid tumors.

Main Results:

• HDAC dual-target inhibitors demonstrate significant potential by combining synergistic anti-tumor activities.
• These inhibitors can potentially overcome drug resistance mechanisms observed in NSCLC treatment.
• Dual-targeting strategies may lead to reduced systemic toxicity compared to single-target agents.

Conclusions:

• HDAC dual-target inhibitors offer a promising therapeutic avenue for non-small cell lung cancer (NSCLC).
• Further research is needed to optimize the design and clinical application of these agents.
• Developing novel HDAC-based dual inhibitors could lead to more effective and safer treatments for NSCLC patients.